Lenalidomide, Bortezomib

DRUG3 trials

Sponsors

University Hospital, Toulouse, Wuerzburg University Hospital

Conditions

Multiple MyelomaMyelomaPreviously Untreated Symptomatic Multiple Myeloma

Phase 2

Frontline Therapy in de Novo Multiple Myeloma Patients Under 65

CompletedNCT01206205

University Hospital, ToulouseMultiple Myeloma

Start: 2009-08-31End: 2012-10-31Updated: 2017-05-12

Phase 3

Study Comparing Conventional Dose Combination RVD to High-Dose Treatment With ASCT in the Initial Myeloma up to 65 Years

CompletedNCT01191060

University Hospital, ToulouseMyeloma

Start: 2010-10-01End: 2018-11-30Updated: 2026-04-06

Lenalidomide, Adriamycin, Dexamethasone (RAD) Versus Lenalidomide, Bortezomib, Dexamethasone (VRD) for Induction in Newly Diagnosed Multiple Myeloma Followed by Response-adapted Consolidation and Lenalidomide Maintenance

Wuerzburg University HospitalPreviously Untreated Symptomatic Multiple Myeloma

Start: 2012-05-31End: 2023-12-31Target: 406Updated: 2023-04-27

Related Papers

Integrated analysis of randomized controlled trials evaluating bortezomib + lenalidomide + dexamethasone or bortezomib + thalidomide + dexamethasone induction in transplant-eligible newly diagnosed multiple myeloma

Frontiers in Oncology2023-11-0216 citations

P10 AN ULTRA-SENSITIVE METHOD FOR SEQUENCING AND MONITORING OF M-PROTEIN IN PERIPHERAL BLOOD (M-INSIGHT)

HemaSphere2023-05-013 citations

Multiple Myeloma Minimal Residual Disease Detection: Targeted Mass Spectrometry in Blood vs Next-Generation Sequencing in Bone Marrow

Clinical Chemistry2021-09-0846 citations

The Genomic and Transcriptomic Landscape of Plasma Cell Leukemia

Blood2020-11-058 citations

Minimal Residual Disease in Multiple Myeloma: Targeted Mass Spectrometry in Blood Vs Next Generation Sequencing in Bone Marrow

Blood2020-11-052 citations

Genome-Wide Somatic Alterations in Multiple Myeloma Reveal a Superior Outcome Group

Journal of Clinical Oncology2020-07-2075 citations

Bortezomib, lenalidomide, and dexamethasone (VRD) is superior to lenalidomide, adriamycin, and dexamethasone (RAD) prior to risk-adapted transplant in newly diagnosed myeloma.

Journal of Clinical Oncology2020-05-202 citations

Health-related quality of life results from the IFM 2009 trial: treatment with lenalidomide, bortezomib, and dexamethasone in transplant-eligible patients with newly diagnosed multiple myeloma

Leukemia & lymphoma/Leukemia and lymphoma2020-02-2243 citations

Patterns of Renal Recovery and Toxicity with Novel Agent-Based Induction Triplets in Newly Diagnosed Multiple Myeloma - an Analysis of Two Prospective Studies By the German DSMM Myeloma Study Group

Blood2019-11-13

Multiple Myeloma Drivers of High Risk and Response to Stem Cell Transplantation Identified By Causal Machine Learning: Out-of-Cohort and Experimental Validation

Blood2017-12-072 citations

Lenalidomide, doxorubicin hydrochloride and dexamethasone versus bortezomib, lenalidomide, and dexamethasone prior to scheduled stem cell transplant in newly diagnosed myeloma.

Journal of Clinical Oncology2017-05-201 citations

Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma

New England Journal of Medicine2017-04-051201 citations